AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/article-1G1-169982463/japan-mhlw-oks-shire.html" title="Facts and information about Japan's MHLW OKs Shire's Elaprase.(Shire Pharmaceuticals Group PLC)(Ministry of Health ,Labor and Welfare)(Brief article)">Japan's MHLW OKs Shire's Elaprase.(Shire Pharmaceuticals Group PLC)(Ministry of Health ,Labor and Welfare)(Brief article)</a>

Close Set up an RSS feed that alerts you when new articles from Pharma Marketletter are available.

Frequently asked questions about RSS feeds

Japan's MHLW OKs Shire's Elaprase.(Shire Pharmaceuticals Group PLC)(Ministry of Health ,Labor and Welfare)(Brief article)

Pharma Marketletter

| October 15, 2007 | COPYRIGHT 2007 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

UK drugmaker Shire says that Japan's Ministry of Health, Labor and Welfare has approved its product Elaprase (idursulfase) for the treatment of Hunter syndrome. The decision means that the drug, a human enzyme replacement therapy, has gained regulatory clearance in 34 countries worldwide since the US Food and Drug Administration first approved it last year (Marketletter July 31, 2006).

Shire president Sylvie Gregoire said that the decision is another step towards making the drug available to Hunter syndrome patients worldwide. She added that the firm greatly appreciated the commitment of Japanese patients to the drug, some of whom ...

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Sylvie Gregoire, Former Biogen Executive Vice President, Named New CEO of...: Press release article from: Business Wire October 5, 2004 700+ words
...GlycoFi, Inc. today announced the appointment of Sylvie Gregoire, Pharm.D., as chief executive officer. She joins the...management team of one of the top 5 biotech companies, Sylvie Gregoire joins GlycoFi with exceptional leadership capabilities and...


Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business.: Press release article from: PR Newswire September 24, 2007 700+ words
...specialty biopharmaceutical company, announced today that Sylvie Gregoire has been appointed President of its Human Genetic Therapies...therapies for patients suffering from genetic diseases," said Sylvie Gregoire, President of Shire HGT. "Elaprase has been successfully...


Biogen appoints Sylvie Gregoire, Pharm.: Press release article from: PR Newswire August 27, 2001 700+ words
Biogen appoints Sylvie Gregoire, Pharm. D., executive vice president, technical operations...Massachusetts - Biogen, Inc. (Nasdaq: BGEN) today announced that Sylvie Gregoire, Pharm. D., has been appointed Executive Vice President...


BIOGEN APPOINTS SYLVIE GREGOIRE, PHARM. D., AS DIRECTOR OF REGULATORY...: Press release article from: PR Newswire May 9, 1995 700+ words
CAMBRIDGE, Mass., May 9 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN) today announced the appointment of Sylvie Gregoire, Pharm. D., as Director of Regulatory Affairs-Europe. She reports to Alain Gilbert, Vice President-Europe...


Biogen Appoints Sylvie Gregoire, Pharm. D., Executive Vice President, Technical...: Press release article from: PR Newswire August 27, 2001 700+ words
CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN) today announced that Sylvie Gregoire, Pharm. D., has been appointed Executive Vice President, Technical Operations. Dr. Gregoire reports to James C. Mullen...


Cubist Pharmaceuticals Appoints Sylvie Gregoire, Pharm. D., to Its Board of...: Press release article from: Business Wire June 12, 2006 700+ words
LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced the appointment of Sylvie Gregoire, Pharm. D., to its Board of Directors. Dr. Gregoire, who has twenty years of pharmaceutical and biotech industry experience...


IDM Pharma Appoints Sylvie Gregoire, Pharm. D., as Executive Chair of the Board...: Press release article from: Business Wire August 15, 2006 700+ words
IRVINE, Calif. -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced the appointment of Sylvie Gregoire, Pharm. D., as Executive Chair of the Board of Directors. Dr. Gregoire has been a board member of IDM since August 2005...


GlycoFi Strengthens Mangement Team; Appoints James Posada, Ph.D., MBA As Senior...: Press release article from: Business Wire June 2, 2005 700+ words
...proprietary compounds. Dr. Posada will report directly to Sylvie Gregoire, Pharm.D., Chief Executive Officer of GlycoFi. Dr...commercializing GlycoFi's proprietary drug molecules," said Sylvie Gregoire CEO of GlycoFi, Inc. "GlycoFi has developed a breakthrough...


IDM Pharma, Inc. - ODAC Panel Investor Conference Call - Final.: News wire article from: Fair Disclosure Wire May 9, 2007 700+ words
...Romet-Lemonne, Chief Executive Officer. Please proceed. DR. SYLVIE GREGOIRE, EXECUTIVE CHAIRMAN OF THE BOARD, IDM PHARMA, INC.: Thank...its] approval. But maybe Sylvie want to add something. DR. SYLVIE GREGOIRE: Y


Q1 2008 Shire Plc Earnings Conference Call - Final.: News wire article from: Fair Disclosure Wire April 25, 2008 700+ words
...Officer; Angus Russell, Chief Financial Officer; and Sylvie Gregoire, President of our Human Genetic Therapies Business. Before...Russell will continue with a financial review of the quarter; Sylvie Gregoire will speak briefly about the acquisition of a new orphan...

For more facts and information, see all results

Source: HighBeam Research, Japan's MHLW OKs Shire's Elaprase.(Shire Pharmaceuticals Group...